Randomized Trialhigh evidence
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.
Nature medicine·March 1, 2026·PMID 41514039
Why it mattersIt provides early clinical evidence that an RNA-based CAR-T approach can achieve meaningful disease modification in autoimmunity without the toxicity and logistical barriers of conventional CAR-T, potentially expanding access to cell therapy for neurologists and internists.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled